Stockreport

Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibi...

Olema Pharmaceuticals, Inc.  (OLMA) 
PDF Pre-clinical results demonstrate that palazestrant, as both a CERAN and a SERD, has a highly differentiated mechanism of action as a potential therapy for advanced ER+/ [Read more]